The most unsettling idea in modern neurodegeneration research is also one of the most human: our own immune system may be helping and hurting at the same time—sometimes within the same timeline, sometimes depending on which cell is doing the reacting.
Personally, I think this “two-faced immunity” framing is where the field finally becomes interesting, because it forces us to stop treating Alzheimer’s, Parkinson’s, and related disorders as purely neuron-only tragedies. The brain is not an immune-free sanctuary. It runs an ongoing security operation—microglia surveil, astrocytes manage the local response, and the blood-brain barrier is maintained like a security gate that can fail. What makes this particularly fascinating is that the immune story doesn’t just sit on the side; it may actually shape when symptoms appear, how fast they worsen, and why therapies succeed for some people and miss for others.
If you take a step back and think about it, the real editorial point here isn’t “immunity causes neurodegeneration.” It’s that immunity is adaptive machinery, and adaptation can go wrong. The question becomes not whether the immune system is involved, but what kind of involvement counts as protective versus destructive—and at what moment in the disease arc.
Microglia: the janitors who might start redecorating
One thing that immediately stands out is the emphasis on innate immune activation—especially microglia—during neurodegeneration. Neurons under stress don’t just “quietly fail”; they emit danger signals, often described as DAMPs (damage-associated molecular patterns). These can include mitochondrial DNA, reactive oxygen species, HMGB1, and even abnormal protein-related signals.
From my perspective, this matters because microglia are built for a job: detect damage, recruit help, clean up debris, and coordinate downstream responses. That early phase can look almost sensible—like a fire alarm that calls the right firefighters. But when the brain is trapped in chronic distress, those same detection systems can become stuck on “high alert,” turning clearance into inflammation and inflammation into further injury.
What many people don't realize is how the immune system translates “danger molecules” into genetic programs. Pattern recognition receptors—like TLRs and receptors such as RAGE—help microglia switch into a reactive state, and that transition can feed pro-inflammatory signaling. The details are technical, but the implication is simple: repeated or prolonged alarm signals may gradually change microglia from responders into contributors.
Personally, I think the most important nuance here is not that microglia “attack neurons” in a cartoonish way. It’s that microglial state change can both reveal and accelerate pathology. For example, the field increasingly discusses “damage-associated” microglia—subtypes that coordinate antigen presentation and interact with other immune layers. That raises a deeper question: is the immune system trying to solve a problem, or is it becoming part of the problem?
Pattern recognition: the brain keeps recognizing itself
In the review literature, aberrant proteins are treated as immune triggers—not just as pathological markers. Amyloid-beta and phosphorylated tau (in Alzheimer’s), and alpha-synuclein (in Parkinson’s and related synucleinopathies) can behave like DAMP-like entities that activate innate immune sensors.
In my opinion, this is one of the field’s biggest conceptual pivots. We often talk about these proteins as if they are inert debris. But if they actively engage immune receptors, they become active participants in disease dynamics. That also helps explain why genetic and pharmacologic experiments that modulate immune pathways can change both inflammation and the burden of misfolded proteins.
A detail I find especially interesting is how interventions targeting certain receptors can have counterintuitive outcomes—sometimes worsening cognitive decline and increasing protein accumulation. Personally, I interpret that as evidence that immune pathways are not uniformly harmful. They can be protective when they help remove or contain pathology, and harmful when they escalate inflammation without effective clearance.
This raises a deeper question for therapy design: how do you suppress enough immune activity to reduce damage, without undermining the brain’s ability to deal with what’s already misfolding? From my perspective, this is why broad immunosuppression has repeatedly failed in many contexts—it doesn’t distinguish “helpful cleanup” from “destructive chronic signaling.”
Inflammasomes and DNA-sensing: when inflammation becomes self-sustaining
Beyond TLR-style signaling, the review also points to inflammasome activation and DNA-sensing systems like cGAS–STING. These pathways are often discussed in immunology as drivers of potent inflammatory responses when the body detects things it shouldn’t. In neurodegeneration, stressed cells can release nucleic-acid signals, and the brain’s immune sensors may interpret that as an existential threat.
What this really suggests is a feedback loop possibility. If inflammatory signaling triggers more cell stress, which releases more danger cues, the system can become self-sustaining. Personally, I think this is where timing becomes everything: if you intervene early—before loops fully lock in—you might interrupt the spiral; if you intervene late, you may mostly be treating the symptom-state rather than the causal engine.
One thing that people frequently misunderstand is that “inflammation” is not one thing. In some stages it might help limit aggregation or coordinate debris clearance. In others, it could amplify toxicity, disrupt tissue environment, and worsen barrier integrity. The editorial takeaway is that inflammation is a process with direction and phase—not a label.
RAGE and TREM2: risk genes that hint at immune centrality
Genetic risk and receptor biology reinforce the immune framing. RAGE expression patterns have been reported across Alzheimer’s, Parkinson’s, and other neurodegenerative conditions, with experiments suggesting that changing RAGE levels can alter cognitive outcomes in models.
But the most striking personal point, for me, comes from TREM2. Genetic studies associate variants in TREM2 (a microglia-associated receptor) with Alzheimer’s risk in a way comparable to major lipid transport genetics like APOE ε4. Personally, I think that magnitude matters because it elevates microglial biology from “interesting contributor” to “credible causal axis.”
From my perspective, this is the kind of evidence that should change how funding and clinical trial design are prioritized. If immune receptors carry risk at such a scale, then the immune system isn’t just a downstream effect of neuronal decline—it likely helps shape the disease’s trajectory.
T cells: the immune system isn’t monolithic
The story becomes more nuanced when adaptive immunity enters. CD4+ T cells show disease-specific effects in models: amyloid-beta–restricted CD4+ T cells can be neuroprotective in Alzheimer’s-like settings, while alpha-synuclein–specific CD4+ T cells can be neurotoxic in Parkinson’s models.
Personally, I think this is the part that makes lay audiences uncomfortable, because it complicates the simplistic “immune = bad” narrative. If some T-cell responses protect while others harm, then the enemy isn’t the immune system. The enemy is the wrong immune specificity, the wrong activation state, or the wrong tissue context.
What many people don't realize is that T cells don’t arrive as generic bullets. Their antigen specificity, effector programming, and local interactions with microglia can determine whether they contribute to inflammation or participate in repair-like signaling. In other words, the immune system’s role depends on how it is “trained” inside the body.
CD8+ T cells add yet another twist. They have been detected in Alzheimer’s and correlate with tau pathology, and similar correlations appear in Parkinson’s. Still, the field emphasizes uncertainty about whether these associations represent causation or reactive recruitment.
If you take a step back and think about it, the larger trend is clear: neurodegeneration research is moving toward cellular choreography. Not “who is in the room,” but “what are they doing together, and when?”
Aging, injury, and viruses: changing the brain’s immune setting
Aging is the strongest epidemiological risk factor, and the immune angle makes that more tangible. In youth, microglia survey; astrocytes support barrier function; T-cell entry into the brain parenchyma is comparatively limited. With age, chronic low-grade inflammation and dysregulation shift the immune baseline.
Personally, I think this is more than background noise. When the immune baseline is altered, identical triggers can produce different outcomes. That could help explain why the same pathology—amyloid deposition, for example—doesn’t yield the same clinical course across people.
Traumatic brain injury introduces another route. Repetitive injury can accelerate neurodegeneration, and after mild injury, DAMP release can activate microglia and engage barrier weaknesses. But repeated injury might also push microglia toward death or dysfunction, allowing other immune cells—like myelomonocytic populations—to enter.
From my perspective, injury doesn’t just “add damage.” It remodels the immune environment. That remodeling might persist, creating a brain that reacts more aggressively to later protein misfolding or stress signals.
Then come viral infections. The review highlights links between both neurotropic and non-neurotropic infections and higher neurodegenerative risk. Personally, I interpret this as evidence that peripheral or systemic immune events can leave lasting imprints in CNS immunity—either by altering barrier function, priming immune cell states, or reshaping antigen presentation.
The real therapy question: when to modulate immunity
The most editorially important takeaway is the insistence on timing and context. Neurodegenerative diseases reflect an interplay of environmental and biological factors that govern the magnitude and timing of immune activation and the programming of microglia, T cells, and other leukocytes.
In my opinion, this is where many clinical conversations go wrong. People want a single lever—turn down inflammation, remove microglia, block receptors, boost immunity—and hope the disease simply obeys. But biology rarely behaves that linearly. Immune pathways can be stage-dependent: early activation might clear aberrant proteins, while prolonged activation can become maladaptive.
What this really suggests is a need for interventions that are not just “immune-directed,” but phase-aware. We may eventually need biomarkers that tell us whether the patient’s immune system is currently in a protective mode or a destructive mode. Otherwise, an immunomodulatory therapy could help one subgroup and harm another, producing confusing trial outcomes.
Personally, I’m also struck by how much the field is learning about cell-intrinsic states—microglia transition through homeostatic to reactive forms, sometimes in TREM2-dependent ways. If cell state determines function, then therapies may need to target state transitions rather than simply suppress activity.
A provocative bottom line
If you want one sentence of opinion, mine would be this: neurodegeneration may be a disease of failed immune problem-solving, not merely failed neurons.
Personally, I think the next wave of progress will come from treating immunity as an evolving system inside the brain—one that can either contain misfolding or amplify it, one that can sometimes protect and sometimes poison the microenvironment. This doesn’t absolve protein pathology; it clarifies that immune signaling can dictate whether protein pathology stays local and manageable or spreads into chronic inflammatory cascades.
What makes this particularly fascinating is the challenge it poses to us intellectually and therapeutically. It asks clinicians and researchers to stop thinking in binaries and start thinking in dynamics—specificity, timing, and cellular choreography.
Journal reference: Latour YL, McGavern DB (2026). Immune signaling and function in neurodegeneration. Journal of Clinical Investigation, 136(8), e199850. DOI: 10.1172/JCI199850.
Would you like the tone to be more skeptical and contrarian (arguing there’s still too much uncertainty), or more hopeful and forward-looking (emphasizing how soon trials could translate into treatments)?
